Explanation
Denosumab
Denosumab,qiven by 6-monthuy subcutaneousinjections.is potemtialy aseffective as bisphosphonates. with
a superior adverse evemt profleby avoiding direct gastrointestinaltoxic effects and oesophaqitis
@1MINENDOCRINE
